Page last updated: 2024-08-22

platinum and veliparib

platinum has been researched along with veliparib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Curigliano, G1
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD1
Appleman, L; Belani, CP; Beumer, JH; Chen, A; Chew, H; Chu, E; Diergaarde, B; Ding, F; Duan, W; Garcia, AA; Giranda, V; Hurley, RM; Ivy, SP; Ji, J; Katz, T; Kaufmann, SH; Kiesel, BF; Lee, JJ; Lin, Y; Manzo, J; Morgan, RJ; Oesterreich, S; Pahuja, S; Parchment, RE; Puhalla, S; Shepherd, SP; Stoller, R; Swisher, EM; Tan, AR; Tawbi, H; Visscher, DW; Wahner Hendrickson, AE; Yu, J; Zhang, Y1

Trials

2 trial(s) available for platinum and veliparib

ArticleYear
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
    Cancer treatment and research communications, 2018, Volume: 14

    Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan

2018
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms

2022

Other Studies

1 other study(ies) available for platinum and veliparib

ArticleYear
Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Benzimidazoles; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Salts; Standard of Care; Triple Negative Breast Neoplasms

2018